Cargando…

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

There is an urgent need to develop new life‐prolonging therapy for pancreatic ductal adenocarcinoma (PDAC). It is demonstrated that improved irinotecan delivery by a lipid bilayer coated mesoporous silica nanoparticle, also known as a silicasome, can improve PDAC survival through a chemo‐immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiangsheng, Jiang, Jinhong, Liao, Yu‐Pei, Tang, Ivanna, Zheng, Emily, Qiu, Waveley, Lin, Matthew, Wang, Xiang, Ji, Ying, Mei, Kuo‐Ching, Liu, Qi, Chang, Chong Hyun, Wainberg, Zev A., Nel, Andre E., Meng, Huan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Full Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967046/ https://www.ncbi.nlm.nih.gov/pubmed/33747719 http://dx.doi.org/10.1002/advs.202002147

Ejemplares similares

Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer
por: Wang, Lu, et al.
Publicado: (2023)

Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
por: Lu, Jianqin, et al.
Publicado: (2018)

Retraction of “Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway”
por: Lu, Jianqin, et al.
Publicado: (2021)

Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers
por: Chattopadhyay, Saborni, et al.
Publicado: (2023)

Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
por: Lu, Jianqin, et al.
Publicado: (2017)

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
por: Wainberg, Zev A., et al.
Publicado: (2017)

Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors
por: Wang, Hua, et al.
Publicado: (2020)

Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration
por: Din, Fakhar ud, et al.
Publicado: (2017)

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
por: Muñoz, Juan Pablo, et al.
Publicado: (2023)

Tumor microenvironment-responsive BSA nanocarriers for combined chemo/chemodynamic cancer therapy
por: Zhang, Ruiyi, et al.
Publicado: (2022)

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
por: Wang, Yue, et al.
Publicado: (2023)

Tumor Targeted Nanocarriers for Immunotherapy
por: Baeza, Alejandro
Publicado: (2020)

Nanocarriers for cancer nano-immunotherapy
por: Rana, Isra, et al.
Publicado: (2022)

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023)

Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
por: Zhang, Jiulong, et al.
Publicado: (2022)

Triple‐Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo‐Immunotherapy in Preclinical Cancer Models
por: Shi, Xiaowei, et al.
Publicado: (2023)

β-lactoglobulin-irinotecan inclusion complex as a new targeted nanocarrier for colorectal cancer cells
por: Bijari, Nooshin, et al.
Publicado: (2019)

Gold nanorod-based multifunctional nanocarrier for synergistic chemo-photothermal therapy in tumors
por: Wang, Yi, et al.
Publicado: (2018)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
por: Brendel, Karl, et al.
Publicado: (2021)

Editorial: Design and synthesis of nanocarriers for enhancement of antigen immunogenicity
por: Yu, Shujuan, et al.
Publicado: (2023)

Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment
por: Wang, Jiandong, et al.
Publicado: (2023)

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
por: Ji, Ying, et al.
Publicado: (2020)

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis
por: Artene, Stefan-Alexandru, et al.
Publicado: (2016)

Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes
por: Epistola, Raisa, et al.
Publicado: (2023)

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
por: Liu, Luman, et al.
Publicado: (2022)

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
por: Yonemori, K, et al.
Publicado: (2009)

Evaluation of cell surface reactive immuno-adjuvant in combination with immunogenic cell death inducing drug for in situ chemo-immunotherapy
por: Walters, Adam A., et al.
Publicado: (2020)

Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy
por: Cai, Shuxian, et al.
Publicado: (2021)

Nanocarrier-based immunotherapy in cancer management and research
por: Singh, Manu Smriti, et al.
Publicado: (2014)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

Cascade-amplifying synergistic effects of chemo-photodynamic therapy using ROS-responsive polymeric nanocarriers
por: Sun, Chun-Yang, et al.
Publicado: (2018)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study
por: Zhang, Hangyu, et al.
Publicado: (2023)

Sulfonated Amphiphilic Poly(α)glutamate Amine—A Potential siRNA Nanocarrier for the Treatment of Both Chemo-Sensitive and Chemo-Resistant Glioblastoma Tumors
por: Krivitsky, Adva, et al.
Publicado: (2021)

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
por: Song, Wantong, et al.
Publicado: (2018)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers
por: Nooraei, Saghi, et al.
Publicado: (2021)

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
por: Liu, Min, et al.
Publicado: (2020)

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
por: Satoh, Taroh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hfjmkkrkjl3djrgp8hcfsra8lf